Zai Lab’s New Drug Application (NDA) for KarXT, a schizophrenia treatment for adults, has been accepted by China’s National Medical Products Administration (NMPA). This submission follows successful Phase 3 trials in China and globally, where KarXT significantly reduced schizophrenia symptoms with a tolerable safety profile. The NDA acceptance is based on positive results from a Phase 1 PK study in China, the Phase 3 China study (ZL-2701-001), and data from global EMERGENT clinical programs.
This NDA acceptance is a crucial step toward addressing the significant unmet needs of over 8 million schizophrenia patients in China. Current treatment options often have limited efficacy and undesirable side effects, leading to high discontinuation rates and hindering patients’ ability to achieve life milestones. KarXT, the first new schizophrenia treatment class in decades, offers a potential alternative with a different mechanism of action than existing antipsychotics.
Technically, the China Phase 3 study mirrored the success of global trials. It met its primary endpoint, showing a statistically significant reduction in the PANSS total score. Key secondary endpoints, including positive and negative symptom subscales, were also met. The safety profile was consistent with previous KarXT trials, with common adverse events including vomiting, tachycardia, nausea, hypertension, dizziness, and diarrhea.
The NMPA’s acceptance of the KarXT NDA signifies potential progress in the schizophrenia treatment landscape in China. If approved, KarXT could offer a new and potentially more effective treatment option for a large patient population, ultimately improving patient outcomes and quality of life. This could also establish Zai Lab as a key player in the Chinese mental health market.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
